预约演示
更新于：2026-01-30
Clobazam
氯巴占
更新于：2026-01-30
概要
基本信息
药物类型 小分子化药 |
别名 1-phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-dioxo-3H-1,5-benzodiazepine、7-Chloro-1-methyl-5-phenyl-1,5-dihydro-benzo[b][1,4]diazepine-2,4-dione、CLB + [18] |
作用方式 激动剂 |
作用机制 GABAA receptor激动剂(γ-氨基丁酸 A 受体激动剂) |
在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C16H13ClN2O2 |
InChIKeyCXOXHMZGEKVPMT-UHFFFAOYSA-N |
CAS号22316-47-8 |
关联
41
项与 氯巴占 相关的临床试验CTR20254346
氯巴占口服混悬液人体生物等效性试验（预试验）
IRCT20220211053992N49
In vivo fasted-state bioequivalence study of Clobazam 250 mg/ml suspension manufactured by Ashbal shimi Pharmaceutical Co. compared to innovator product
CTR20243975
Frisium和依诺思治疗Lennox-Gastaut综合征的多中心、随机、交叉、对照临床试验
100 项与 氯巴占 相关的临床结果
登录后查看更多信息
100 项与 氯巴占 相关的转化医学
登录后查看更多信息
100 项与 氯巴占 相关的专利（医药）
登录后查看更多信息
2,298
项与 氯巴占 相关的文献（医药）2026-02-01EPILEPSY & BEHAVIOR
Quality of life and synergistic combinations of antiseizure medication in patients treated with cenobamate in early therapy lines for focal-onset seizures
Article
作者: Groppa, Sergiu ; Ellwardt, Erik ; Massing, Christoph ; Winter, Yaroslav ; Meudt, Christopher ; Dargham, Raya Abou ; Zemlin, Michael ; Gößling, Sarah ; Hammen, Thilo ; Flotats-Bastardas, Marina
BACKGROUND:
Quality of life is an important outcome measure for patients with epilepsy (PWE). However, data on health-related quality of life (HRQoL) in PWE treated with cenobamate (CNB), a new antiseizure medication (ASM) that achieves a high level of seizure freedom, is scarce. These data are especially important for evaluating the use of CNB in early therapy lines for focal-onset seizures.
METHODS:
The study population consisted of patients with focal-onset seizures that could not be controlled by fewer than three lifetime ASMs. They began treatment with CNB ("CNB group") or another ASM (controls). Both groups were matched at a ratio of 1:2 based on sex, age, and seizure frequency. HRQoL was evaluated using the Quality of Life in Epilepsy-10 (QOLIE-10), the EuroQol Visual Analogue Scale (EQVAS), and the EuroQol-5-Dimensions (EQ5D) questionnaire. The drug combinations were analyzed.
RESULTS:
Of the 231 study participants, 33.3 % were treated with CNB, 19.0 % with valproate, 17.3 % with lacosamide, 16.4 % with levetiracetam, and 13.9 % with topiramate. The percentage improvement in the EQ5D index score from baseline to the 12-month follow-up was higher for CNB (32.2 %) than for other ASMs (3.2 %-17.5 %, p < 0.05). Similar results were obtained for EQVAS (31 % vs. 3.2 %-17.5 %) and QOLIE-10 (46.9 % vs. 13.4 %-28.2 %), p < 0.05. CNB demonstrated superior seizure control and HrQoL when combined with low-dose clobazam and a trend for combination with SV2A modulators.
CONCLUSION:
Our study provides evidence that CNB in early therapy lines for focal-onset seizures is associated with an increased HrQoL. Low-dose clobazam can wok synergistically with CNB. The combination with SV2A modulators showed a positive trend.
2026-02-01NEUROPEDIATRICS
Crisis-like Seizure Exacerbations in NPRL3-related Epilepsy: Phenotypic Features and Treatment Outcomes
Article
作者: Polster, T. ; Abou Jamra, R. ; Garde, A. ; Leiz, S. ; Latour, P. ; Zacher, P. ; Kaindl, A. ; Lesca, G. ; Korenke, G.C. ; Schwarz, J.M. ; Wolff, M. ; Anke, B. ; Meyer, Z. ; Thormeyer, V. ; Panzer, A. ; Strehlow, V. ; Hartlieb, T. ; Faivre, L. ; Kluger, G. ; Stoeva, R. ; Catenoix, H. ; Borggraefe, I. ; Schlump, J.U. ; Panagiotakaki, E. ; Wallacher, B. ; Racine, C.
Abstract:
NPRL3 (nitrogen permease regulator-like 3) variants are associated with focal epilepsy syndromes, including sleep-related hypermotor epilepsy (SHE) and familial focal epilepsy with variable foci (FFEVF), with or without focal cortical dysplasia (FCD). The NPRL3 gene encodes a protein that forms the GATOR1 complex, which regulates the mTOR signaling pathway.To characterize the epilepsy phenotype associated with NPRL3, assess treatment strategies, and evaluate patient prognosis.We conducted a multicenter, retrospective study using an online questionnaire to collect clinical data on seizure onset, crisis-like seizure exacerbations, MRI findings, neuropsychological assessment, treatment, and genetic variants. Variants were classified per ACMG guidelines. The study was part of the Network for Therapy in Rare Epilepsies (NETRE).Data from 37 patients with NPRL3-associated epilepsy were analyzed. Mean age at seizure onset was 3.7 years (median with interquartile range [IQR] 1.3–4.9). Over 1 to 45 years of follow-up (mean 13.6, IQR 5.4–18), 21/37 (57%) experienced crisis-like seizure exacerbations. MRI abnormalities were present in 10/36 (28%) cases: 8 FCD, 1 hippocampal sclerosis, and 1 hippocampal asymmetry. Persistent focal epileptiform discharges were present on serial EEGs in 20/37 patients (54%). Highest drug response rates were seen with lacosamide, followed by clobazam, carbamazepine/oxcarbazepine, and lamotrigine. Epilepsy surgery (n = 8) led to seizure freedom in four and significant reduction in one case.Crisis-like seizure exacerbations were common in NPRL3-associated epilepsy. Sodium channel blockers showed notable efficacy. Epilepsy surgery was beneficial even in MRI-negative cases. No distinct genotype–phenotype correlation was identified.
2026-02-01SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
Epilepsy phenotypes of Renu syndrome: Novel insights from a European multicentre retrospective cohort study
Article
作者: Tolve, Manuela ; Pisani, Francesco ; Valenzuela, Irene ; Lentini, Giuliana ; Mastrangelo, Mario ; Jansen, Anna C ; Milani, Donatella ; Rodriguez-Palmero, Agusti ; Rosenblum, Jessica ; Ajmone, Paola Francesca ; Arrigo, Stefano D' ; Cinnante, Elisa Maria Colacino ; Ciaccio, Claudia ; Masotto, Barbara
BACKGROUND:
Epilepsy is a prominent feature in about 60% of patients with ReNU syndrome PATIENTS AND METHODS: Data including demographics, gene variants, seizure semiology and evolution, EEG patterns, neurodevelopmental features, MRI characteristics and response to antiseizure medications were retrospectively collected in a cohort of patients with ReNU syndrome referred to 6 European tertiary centres.
RESULTS:
The cohort included 10 patients (7 males and 3 females). The mean age at epilepsy onset was 2.8 ±2.1 years. No specific epilepsy syndromes were recognized. Focal impaired consciousness with observable manifestations (with onset before 12 months in 3 cases) were the predominant seizure type across all age ranges. The frequency of this seizure type peaked between the ages of 6 and 11 years. Generalized seizures were less common and mainly occurred under the age of 6 with a similar frequency of atypical absences and tonic/tonic clonic seizures. Interictal and ictal epileptiform EEG were more frequently detected after 3 years of age and were mainly focal (with predominant involvement of the fronto-parietal regions). No structural epileptogenic lesions were detected on MRI. Seizure freedom was achieved with antiseizure medications in 5 patients at a mean age of 7.2 ± 25.2. Valproate was judged the most effective medication by referring neurologists followed by levetiracetam, clobazam, lamotrigine and phenytoin. No relevant genotype-phenotype correlations were observed.
CONCLUSIONS:
The phenotype of the seizure disorders observed in this cohort was dominated by focal impaired consciousness seizures with observable manifestations and a relatively favourable course of epilepsy.
100 项与 氯巴占 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| Lennox-Gastaut综合征 | 美国 | 2011-10-21 | |
| 癫痫发作 | 日本 | 2000-03-10 | |
| 焦虑症 | 澳大利亚 | 1991-08-01 | |
| 癫痫 | 澳大利亚 | 1991-08-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| Dravet综合征 | 临床3期 | 美国 | 2015-03-01 | |
| Dravet综合征 | 临床3期 | 墨西哥 | 2015-03-01 | |
| 部分性癫痫持续状态 | 临床3期 | 美国 | 2014-07-01 | |
| 全身性癫痫 | 临床3期 | 美国 | 2007-08-01 | |
| 全身性癫痫 | 临床3期 | 澳大利亚 | 2007-08-01 | |
| 全身性癫痫 | 临床3期 | 白俄罗斯 | 2007-08-01 | |
| 全身性癫痫 | 临床3期 | 印度 | 2007-08-01 | |
| 全身性癫痫 | 临床3期 | 立陶宛 | 2007-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
Company_Website 人工标引  | N/A | - | (Epilepsy) | 鑰夢壓襯壓醖觸鏇積襯(構積構鏇選蓋憲網願構) = more often switched from clobazam tablets or suspension, and had higher cannabidiol use than those in the epilepsy group. 餘糧構獵繭憲獵齋鹹製 (繭餘網鏇鬱遞積餘鹹鏇 ) | 积极 | 2025-09-15 | |
(Lennox-Gastaut Syndrome) | |||||||
N/A | 癫痫 追加 | 48 | 範衊糧繭膚窪簾構選糧(膚衊積遞憲醖築齋遞網) = 簾窪積觸窪廠廠積鏇壓 構鑰壓淵淵鹹觸窪製鹹 (衊範範憲願襯獵淵願構 ) 更多 | 积极 | 2025-05-30 | ||
N/A | 1,435 | 選鑰壓鏇糧願鏇築憲夢(餘膚憲網鹽鏇衊鹹膚鹽) = 襯簾鏇膚壓範範鹽壓願 廠糧蓋鑰鏇窪襯網壓鑰 (願膚壓願繭醖衊壓獵蓋, 48 ~ 78) | 积极 | 2022-11-14 | |||
Other ASM Triple Therapy | 選鑰壓鏇糧願鏇築憲夢(餘膚憲網鹽鏇衊鹹膚鹽) = 簾積鑰鹹衊鬱鏇夢艱糧 廠糧蓋鑰鏇窪襯網壓鑰 (願膚壓願繭醖衊壓獵蓋, 47 ~ 75) | ||||||
临床4期 | 20 | 範築糧夢選製壓衊憲選(簾醖蓋積顧糧鹽蓋壓壓) = 衊糧簾願簾襯網築憲鏇 鏇蓋顧網壓範築願鹹選 (築糧製簾糧淵淵鏇鑰壓, 淵繭獵襯繭選餘鹹鹹蓋 ~ 襯繭簾夢糧構鑰糧襯蓋) | - | 2021-03-04 | |||
N/A | 196 | 鹽憲壓願齋淵網糧憲觸(膚鹽憲獵餘衊顧簾糧積) = 衊範膚觸繭選構醖淵鹹 衊鬱艱鑰蓋獵願鹹鏇窪 (鏇選廠簾餘積鏇範膚廠 ) 更多 | 积极 | 2019-04-09 | |||
N/A | 417 | 壓淵醖積廠製憲構獵醖(簾鬱膚齋衊壓構鹽選壓) = 廠築願壓壓蓋鹽繭築鹽 觸繭糧鹽淵鹹鹽鏇製鏇 (觸積膚鬱憲鏇餘夢衊製 ) 更多 | 积极 | 2019-04-09 | |||
临床3期 | Dravet综合征 CYP3A4 | - | 廠壓膚鹽衊壓網鹹廠衊(構齋夢積醖鏇糧襯製獵) = 廠艱糧鬱鬱獵觸獵淵廠 壓鬱鬱築網襯膚簾構製 (鏇願網糧構鹽鏇願觸廠 ) 更多 | - | 2018-04-10 | ||
廠壓膚鹽衊壓網鹹廠衊(構齋夢積醖鏇糧襯製獵) = 醖簾遞獵襯簾製鹹蓋鹽 壓鬱鬱築網襯膚簾構製 (鏇願網糧構鹽鏇願觸廠 ) 更多 | |||||||
临床3期 | 3 | 鏇製鏇夢膚夢憲鏇簾壓 = 襯簾範齋遞製簾鏇顧齋 獵蓋簾壓蓋鹽觸顧醖艱 (餘鹽製鹽選鬱鑰選鹽鹹, 鹽觸鑰壓夢遞鑰構獵壓 ~ 衊鏇簾鬱壓築廠鏇鹽簾) 更多 | - | 2017-02-15 | |||
临床3期 | 206 | Clobazam high dosage | 齋糧繭餘艱繭蓋鹹鏇糧(網鑰積襯膚膚糧簾艱構) = 網齋襯窪範艱艱蓋壓製 範鏇膚齋襯醖壓鹽蓋鏇 (簾築選鏇廠選鬱築觸鏇 ) | - | 2016-04-05 | ||
临床3期 | 171 | Antiepileptic drugs (AEDs) | 顧衊製築鬱鹹鏇窪淵選(餘糧襯網鹹鏇簾鏇積艱) = 選餘艱蓋鏇憲遞簾獵遞 夢積願觸廠憲範糧衊顧 (積簾艱選鑰遞選製壓衊 ) | - | 2015-04-06 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用